This 2 stage study will investigate the effectiveness and safety of a combination pharmacotherapy for methamphetamine use disorder. Stage 1 will include 20 participants with moderate or severe stimulant use disorder who will receive a monthly injection of extended-release depot naltrexone plus once-daily bupropion extended-release tablets for 8 weeks. If Stage 1 data documents success in at least 3 “responder” study participants, Stage 2 will follow utilizing the same protocol as in Stage 1, to enroll an additional group of 29 participants.
Get this Publication
Formed with SAMHSA to reduce the gap between research results and treatment.